FDA Clearance for MyoVista wavECG Gives HSCS a Legacy Option, but Core Thesis Unchanged

What happened

HeartSciences announced FDA 510(k) clearance for its MyoVista wavECG device as a 12-lead resting electrocardiograph, covering acquisition and advisory interpretation for adult and pediatric patients. This is a milestone for the legacy cardiac diagnostics business, but the master report shows HSCS remains pre-revenue with minimal cash and a going-concern warning. The clearance does not address the company's near-term liquidity squeeze or the pending Fortitude reverse merger, which would leave legacy holders with only ~5% of post-close equity. The device still requires commercialization investment, and the company's historical execution has been weak. The FDA clearance may provide a fallback if the merger fails, but the dominant value driver remains the merger outcome and financing risk.

Implication

Investors should treat the FDA clearance as a secondary consideration behind the Fortitude merger and the company's survival financing. The clearance gives HSCS a potential standalone product if the merger collapses, but even then the company would need significant capital to commercialize and compete against established ECG players. The stock may see a short-term pop, but the structural issues remain: only $3.397M cash as of Q1 2026, Streeterville note redemptions resuming after October 31, 2026, and legacy shareholders getting minimal economics in the merger. The key milestones to watch remain the proxy filing and shareholder vote on the merger, not additional product clearances. A rational investor should not treat this news as a thesis changer but rather a small positive option value in a distressed situation.

Thesis delta

The primary thesis that HSCS is a reverse-merger vehicle with pre-close financing risk remains intact. The FDA clearance adds a minor positive option for the legacy business, but it does not change the probability-weighted outcome, which still skews negative for legacy holders. The clearance does not improve the company's near-term cash position or reduce the dilutive impact of the merger.